Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.1.19 (
NOS
)
7,285
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Endothelial nitric oxide synthase (eNOS) catalyzes the conversion of l-arginine and molecular oxygen into l-citrulline and nitric oxide (NO), a gaseous second messenger that influences cardiovascular physiology and disease. Several mechanisms regulate eNOS activity and function, including phosphorylation at Ser and Thr residues and protein-protein interactions. Combining a tandem affinity purification approach and mass spectrometry, we identified
stromal cell-derived factor 2
(
SDF2
) as a component of the eNOS macromolecular complex in endothelial cells.
SDF2
knockdown impaired agonist-stimulated NO synthesis and decreased the phosphorylation of eNOS at Ser(1177), a key event required for maximal activation of eNOS. Conversely,
SDF2
overexpression dose-dependently increased NO synthesis through a mechanism involving Akt and calcium (induced with ionomycin), which increased the phosphorylation of Ser(1177) in eNOS. NO synthesis by iNOS (inducible
NOS
) and nNOS (neuronal
NOS
) was also enhanced upon
SDF2
overexpression. We found that
SDF2
was a client protein of the chaperone protein Hsp90, interacting preferentially with the M domain of Hsp90, which is the same domain that binds to eNOS. In endothelial cells exposed to vascular endothelial growth factor (VEGF),
SDF2
was required for the binding of Hsp90 and calmodulin to eNOS, resulting in eNOS phosphorylation and activation. Thus, our data describe a function for
SDF2
as a component of the Hsp90-eNOS complex that is critical for signal transduction in endothelial cells.
...
PMID:Stromal cell-derived factor 2 is critical for Hsp90-dependent eNOS activation. 2628 23